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Abstract
In malignant gliomas, the integrin adhesion receptors seem to play a key role for invasive
growth and angiogenesis. However, there is still a controversy about the expression and the
distribution of avb3 integrin caused by malignancy. The aim of our study was to assess the
extent and pattern of avb3 integrin expression within primary glioblastomas (GBMs) com-
pared with low-grade gliomas (LGGs). Tumor samples were immunostained for the detec-
tion of avb3 integrin and quantiﬁed by an imaging software. The expression of avb3 was
foundtobesigniﬁcantlyhigherinGBMsthaninLGGs,wherebyfocalstrongreactivitywas
restricted to GBMs only. Subsequent analysis revealed that not only endothelial cells but
also, to a large extent, glial tumor cells contribute to the overall amount of avb3 integrin in
the tumors.To further analyze the integrin subunits, Western blots from histologic sections
were performed, which demonstrated a signiﬁcant difference in the expression of the b3
integrin subunit between GBMs and LGGs. The presented data lead to new insights in
the pattern of avb3 integrin in gliomas and are of relevance for the inhibition of avb3
integrin with speciﬁc RGD peptides and interfering drugs to reduce angiogenesis and tumor
growth.
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INTRODUCTION
Gliomas are the most common brain-derived neoplasms with glio-
blastoma (GBM) multiforme being the most frequent and also the
most malignant subtype. Marked tumor cell proliferation, rapid
invasion into the surrounding brain tissue and intense microvascu-
lar angiogenesis are the biologic hallmarks of malignant gliomas
(25, 26, 34). They depend on the complex interactions of tumor
cells with the extracellular matrix (ECM) and neighboring endot-
helial cells as well as various other cell types (14, 40). These
mechanisms include signaling via integrins, which are involved in
adhesive properties of proliferating cells and play fundamental
roles in the regulation of migration and invasion of tumor cells as
well as of neoangiogenesis (23, 36).The integrin family consists of
24 different heterodimeric receptors of two transmembrane sub-
units of which the 18a and 8b subunits are known at present (5, 23,
41). In contrast to many other cell-surface receptors, integrins are
not only able to transduce signals to the interior of the cells
(“outside-in” signaling) but can also transmit information about
the activational state of the cells to their microenvironment
(“inside-out” signaling) (13, 41).
Theintegrinsavb3andavb5havebeendemonstratedtobeneces-
sary for tumor-induced angiogenesis in a variety of tumors,
particularly malignant gliomas via basic ﬁbroblast growth factor
(bFGF) and tumor necrosis factor a (TNF-a) (9, 10, 15). Indeed,
integrin avb3 has been found to be located in small blood vessels in
GBMs, where it is thought to promote the extensive tumor progres-
sion, while in the tissue of the normal brain, it is barely detectable
(16). Interestingly, immunohistochemical studies of autopsy mate-
rial from patients with brain tumors revealed that the expression of
integrin avb3 might not be restricted only to proliferating endothe-
lial cells (32). Integrin avb3 was also detected and colocalized with
matrix metalloproteinase 2 (MMP-2) at the surface of invasive
tumor cells (6, 11).Yet, the level of avb3 integrin expression and its
cellulardistributioncausedbymalignancyhasnotbeenexpounded
up to now. This has become even more important as avb3 integrin
antagonists have reached phase I/IIa clinical trials in patients with
malignant gliomas, where they are used in combination with
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undertaken to elucidate the expression level and pattern of the
integrinavb3inhigh-andlow-gradegliomas(LGGs)byanalysisof
snap-frozen tumor samples.
MATERIALS AND METHODS
Patients and tissue samples
The brain tissues were obtained from 20 primary GBMs, corre-
sponding to the World Health Organization (WHO) grade IV, and
ﬁvediffuseastrocytomas,correspondingtoWHOgradeII.Written
informed consent was obtained from all patients for the scientiﬁc
use of tumor tissue.The histologic diagnosis was made on parafﬁn
sections according to the WHO criteria (25). For the immunohis-
tochemical analysis of avb3 integrin expression (GBM: n = 12;
LGG:n = 4;histologicallysuitablequality)andWesternblotanaly-
sis(GBM:n = 20;LGG:n = 5),correspondingtissuesampleswere
snap frozen in liquid nitrogen and processed as described below.
Additionally, samples of ﬁve different solid peripheral tumors
(malignant melanoma, neuroﬁbroma, skin cancer metastases,
malignant ﬁbrillary histiocytoma and sarcoma; n = 1 each) were
processed (kindly provided by the Department of Pathology,Tech-
nical University of Munich, Munich, Germany).
Histologic and immunohistochemical staining
Parafﬁn sections
For the histologic tumor grading, tissues from all patients were
ﬁxedforatleast24 hinphosphate-bufferedformalin(4%,pH 7.3),
dehydrated in graded ethanol followed by xylol and embedded in
hot parafﬁn. Sections (6 mm) were cut from a cold parafﬁn block
and mounted on slides.After drying and deparafﬁnation in graded
alcohol, routinely Hematoxilin & Eosin (H&E), Elastica van
Gieson and Gomorri stains were performed. Additional immuno-
histochemical investigations included the proliferation index by
stainingproliferationmarkerMIB-1andglialﬁbrillaryacidprotein
(GFAP) according to standard procedures (antibodies were
obtained from DakoCytomation, Hamburg, Germany).
Cryosections
Cryosections of 6-mm thickness (GBM: n = 12; LGG: n = 4; histo-
logicallysuitablequality)weremountedonglassslides(Superfrost
Plus, Menzel, Braunschweig, Germany) and postﬁxed with 4%
paraformaldehyde and acetone (each 10 minutes at 4°C). After a
short equilibration in phosphate-buffered saline (pH 7.3) over
10 minutes at room temperature, immunohistochemical stains
were performed simultaneously and automatically to reach a
maximum of accuracy (BenchMark® and software NexES v9.20,
Ventana, Strasbourg, France). As primary antibodies, we used
either polyclonal anti-GFAP (1:1600, DakoCytomation, Hamburg,
Germany), monoclonal anti-CD31 (1:50, DakoCytomation,
Hamburg, Germany) or monoclonal anti-avb3 integrin (1:100,
cloneLM609,Chemicon,Temecula,CA,USA)dilutedinantibody
diluent (Antibody Diluent, Ventana, Strasbourg, France). The
primary antibody was incubated over 32 minutes at 37°C (soft-
ware: “option 1 per hand”). Respective application of polyclonal
biotinylated secondary antibodies (1:150, DakoCytomation,
Hamburg, Germany, secondary antibody incubation 32 minutes
at 37°C, software: “option 2 by dispenser”) was followed by
alkaline phosphatase conjugated streptavidin (enhanced SA-AP
over 12 minutes, Ventana, Strasbourg, France). Visualization was
achieved by the generation of Fast Red over 20 minutes at room
temperature as prescribed by the manufacturer (enhancer/naphthol
4 minutes, Fast Red A 8 minutes, Fast Red B 8 minutes, Ventana,
Strasbourg, France). Subsequently, the slides were counterstained
with hematoxylin (hematoxylin 4 minutes, bluing reagent
4 minutes) and 4′-6-Diamidino-2-phenylindole (DAPI).The slides
were dehydrated by an ascending ethanol sequence (50%, 70%,
98%, 100%) and xylene, and ﬁnally covered.
All immunohistochemical staining procedures and antibody
concentrations were adjusted to avoid overstaining (saturation),
understaining (beyond detection limit) or non-speciﬁc background
artifacts. In detail, for staining avb3 integrin, series of dilutions
of the secondary antibody (previous incubation without primary
antibody) were performed on positive control (xenotransplanted
human M21 melanoma cells expressing avb3, see below) to deter-
mine the highest concentration where no background artifacts or
non-speciﬁc binding occurred (= maximum sensitivity of second-
ary detection). Then, based on this setting, series of the primary
antibody concentration were tested on the positive control. As
staining intensity demonstrates a saturation effect, the concentra-
tion developing a moderate staining intensity (about half of the
maximum intensity of a blank sample) was further used. At this
concentration,nonon-speciﬁcbackgroundstainingwasdetectable.
Murine tumor models
Xenotransplanted human melanoma cells (M21) expressing avb3
integrin (12, 19) served as a positive immunohistochemical
control. Cell culture conditions for M21 were set up as described
elsewhere (20). The experimental protocol involving animals was
approved by the Committee of Veterinarian Medicine of the State
ofBavaria;thehandlingofanimalswasperformedaccordingtothe
standards set by the Committee ofVeterinarian Medicine.
Toobtainthetumortissue,themicewereinjected1.5 ¥ 106M21
subcutaneously, which led to the formation of tumors with a diam-
eter of approximately 8 mm within 8 weeks. Four weeks after
inoculation, the tumors were dissected, cut and frozen for further
processing (20).
Analysis of immunohistochemical staining
The immunohistochemical detection of avb3 integrin was deter-
mined by a special imaging software, which was calibrated for this
purpose. Within a selected area, it measured (i) the mean intensity
of the desired immunohistochemical staining and (ii) the immuno-
histochemically positive fraction at a desired immunohistochemi-
cal staining intensity (software written by the author B. Krebs)
(33).
In detail, all sections stained in parallel were scanned through an
upright microscope (Axiovert 200M and Axiocam MRc5, Carl
Zeiss AG, Jena, Germany), keeping the settings including light
intensity constant. In the digitized pictures (983 ¥ 737 mm), the
area of tissue was selected by excluding possible empty areas of
glass light only. Consequently, the measurement was related to
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tochemical detection. Thereby, the software mathematically
extracted the component of the desired immunohistochemical
staining per pixel (Fast Red maximum emission: 580 nm) and
determined its intensity. From this data, the mean intensity of the
immunohistochemical staining was calculated. For calibrating the
intensity measurement, a sample stained in parallel of xenotrans-
planted human M21 melanoma cells expressing avb3 was used.
This sample acted as a positive control (12, 19) and was set to
100%.The tissue that was counterstained only served as a negative
control (set to 0%). The procedure resulted in (i) the relative level
of avb3 integrin expression in the respective sample (= mean
immunohistochemical staining intensity). In addition, to evaluate
thedistributionpatternoftheimmunohistochemicalstaininginten-
sity within the selected area, the fraction of immunohistochemi-
callypositiveareaatadesiredintensitylevelwascalculated.Inthis
study, three different levels of staining intensity deﬁned as mild,
moderate or strong (about 25%, 50% and 75% of positive control)
were investigated.This resulted in (ii) a quantiﬁcation based on the
desired levels of staining intensity (= fraction at different intensity
levels).
Western blot
Parallel to the immunohistochemical stainings, Western blotting
wasperformedfromthefrozensectionsofthebraintumorbiopsies
asdescribedelsewhere(27).Inbrief,frozenbrainsectionswerecut
in 6-mm sections and mounted on glass slides (same as for immu-
nohistochemical stainings).Afterwards, the sections were overlaid
with section lysis buffer [2% sodium dodecyl sulfate (SDS),
0.05 M dithiothreiotol, 10% glycerol, 1 mm EDTA, 16 mm Tris-
HCl, pH 7.2] using a total volume of 20 mL per 10 mm2 of tissue.
The solubilized tissue was collected, boiled for 10 minutes and
subjected to sodium dodecyl sulfate polyacrylamide gel electro-
phoresis.Theverysmallamountoftissueusedinthisstudywasnot
suitable for standard methods of protein measurement (eg, Brad-
ford assay). Therefore, a protein loading control was determined
separately (b-actin, see beyond). Proteins were electrophoretically
separated (New Page Gel 12%, Invitrogen, Karlsruhe, Germany)
with 100 V over 24 minutes in running buffer [0.1% SDS, 1 mm
EDTA, 15 mm 3-(N-morpholino) propansulphonic acid (MOPS),
50 mmol Tris-HCl, pH 7.2]. After that, the proteins were trans-
ferred to a polyvinyldiﬂuoride (PVDF) membrane (0.45 mm,
Immobilon, Millipore, Eschborn, Germany) by a semidry blotting
technique with freshly prepared blotting buffer (20% methanol,
192 mmol glycin, 25 mmol Tris-base, pH 8.3). Next, the PVDF
membranes were blocked in blocking buffer (0.05% w/v casein,
0.5% v/v Tween in phosphate buffer saline, pH 7.4) over 1 h at
room temperature. The primary antibodies against integrin sub-
units (polyclonal rabbit anti-integrin av subunit AB1930 and
polyclonal rabbit anti-integrin b3 subunit AB1932; Chemicon,
Temecula,CA,USA)weredilutedintherespectiveblockingbuffer
(1:1000) and incubated overnight at 4°C. After a washing step,
bound antibodies were labeled using a secondary antibody coupled
to alkaline phosphatase (1:2000 polyclonal goat anti-mouse and
anti-rabbit immunoglobulin/AP, DakoCytomation, Hamburg,
Germany) over 45 minutes. Visualization followed a second
washing step using chromogen nitroblue tetrazolium (NBT) salt
and 5-bromo-4-chloro-3-indulylphosphate (BCIP) according to
standard protocols (28). The wet blots were scanned using a high-
resolutionﬂatbedscannerbeforereprobing.Forthedetectionofthe
endothelial component, the blots were reprobed with anti-CD31
(CD31); for the assessment of the amount of tissue, Western blots
were reprobed with anti-b-actin (Actin I-19, Santa Cruz Biotech-
nology, Heidelberg, Germany) as the ubiquitous component of the
cytoskeleton (21). Densitometric measurements were performed
with the software TotalLab V 2.01 (Nonlinear Dynamics, New-
castle uponTyne, UK) by using series of dilution for calibration of
the concentration and a protein ladder (Invitrogen, Karlsruhe,
Germany) for the calibration of the molecular weights.
PCR
For the analysis of the mRNA expression of integrin subunits av
and b3, equal amounts of tumor tissue from GBMs (n = 5) and
LGG (n = 3) patients were homogenized and suspended in
TRIZOL® reagent (Invitrogen, Karlsruhe, Germany). RNA was
isolated according to the manufacturer’s instructions (Invitrogen,
Karlsruhe, Germany). The ﬁrst-strand cDNA synthesis was done
by MMLV-RT (New England Biolabs, Frankfurt, Germany).
Primers were designed according to the sequences of ITAV [acces-
sion number NM_002210; forward primer (2692–2716):
5′-CTATGAGCTGAGAAACAATGGTCC-3′; reverse primer
(3351–3373): 5′-GCTGCTCCCTTTCTTGTTCTTC-3′] for inte-
grin subunit av and ITB3 [accession number NM_00212; forward
primer (1859–1881): 5′-CTGTATCCAGCCGGGCTCCTATG-3′;
reverse primer (2346–2369): 5′-GCCCCGGTACGTGATATT
GGTGAA-3′] for integrin subunit b3.The analysis and comparison
of the sequences were performed with the DNAstar software
(GATC Biotech, Konstanz, Germany). All primers were blasted
against the www-databases. PCR for amplifying total cDNA as the
template was performed for up to 30 cycles with denaturation for
30 s at 95°C, annealing for 45 s at 64°C and elongation for 60 s at
72°C with theAdvantage™ 2 PCR Enzyme Systems (Takara, Otsu,
Japan).
Statistics
Staining intensities and densities of immunopositive structures as
well as densitometric measurements of the Western blots were
tested for normal distribution and groups were compared by Stu-
dent’s t-test for unpaired values and unequal variances. All values
were given with standard deviation.
RESULTS
Two types of patterns of avb3 and
CD31 expression
Immunohistochemical staining of avb3 integrin was investigated in
sections of GBMs (n = 12), diffuse low-grade astrocytomas (n = 4)
as well as non-CNS tumors (n = 5).The expression of avb3 integrin
was found in the microvessels as well as in the glial tumor cells.
The majority of avb3 expression in glial tumors was located in
samples from GBMs, which are characterized by extensive prolif-
eration of pleomorphic glial cells accompanied by microvascular
proliferates with branching glomeruloid vessels. A sample of an
HE stain is given in Figure 1A. Figure 1C,D demonstrates the
Integrin avb3 in Gliomas Schnell et al
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and a hypercellular zone (mid) surrounding the necrotic areas
(right).The staining for avb3 integrin, shown in Figure 1C, demon-
strates a high endothelium-associated expression in this hypercel-
lular zone. This expression is almost identical to the staining
of endothelial marker CD31, as demonstrated in Figure 1D
(microvascular association). Nevertheless, numerous tumor cells,
especially enlarged giant pleomorphic astrocytes, show a strong
immunoreactivity for the avb3 integrin, too. In other samples or
areas with dense tumor growth, the expression of avb3 integrin
seemstobeassociatedtoglialtumorcellsaswell.Atypicalsample
is demonstrated by an overlay of ﬂuorescent stainings of avb3 inte-
grin and CD31 in Figure 1B. The small branched proliferating
microvessels marked by CD31 in red are only partially colocalized
withtheexpressionoftheavb3integriningreen,whichispredomi-
nantlylocatedintheglialtumorcells(glialassociation).Thenuclei
are counterstained in blue. In contrast to the GBMs, a low expres-
sion of avb3 integrin is found in WHO grade II diffuse astro-
cytomas, where the staining was more diffuse and only barely
associated with the microvessels (Figure 2B).
avb3 Protein expression is associated
with malignancy
The different samples were simultaneously stained for avb3
integrin (Figure 2A,B) and analyzed via an imaging software
(Figure 2C,D). The measurements were calibrated to xenotrans-
planted human melanoma cells (M21) expressing avb3. These
acted as a positive control and were set to 100% integrin avb3
expression. The overall mean staining intensity of avb3 integrin in
GBMs reached 76.53  12.08%, which was signiﬁcantly higher
than in LGGs with 58.43  2.30% (P < 0.05, Figure 3A). In
comparison, the samples of the non-CNS tumors reached
85.18  11.95%, (P < 0.05).
To investigate the expression pattern in more detail, the fraction
of immunohistochemically positive structures (density) were cal-
culated for mild, moderate and strong positive detection of avb3
integrin (demonstrated by different colors in Figure 2C,D). In
the samples of GBMs, 54.62  23.52% of all tissue were found at
least mildly stained, whereas the samples of LGGs reached only
22.20  14.99% (P < 0.05, Student’s t-test; Figure 3B).The mod-
erate staining of avb3 integrin was nearly exclusively associated
with malignancy, with 9.07  9.25% in GBMs and 0.06  0.07%
in low-grade astrocytomas (P < 0.05, Student’s t-test). The strong
staining intensities were restricted to GBMs only (2.83  4.08%;
Figure 3B). Therefore, the average avb3 integrin expression in
GBMs exceeds avb3 integrin expression in LGGs by far. However,
different GBMs show a very heterogeneous expression of avb3
integrin, which ranges from slightly to very strong integrin expres-
sion, similar to high expressing non-CNS tumors.
Glioma cells substantially contribute to avb3
integrin expression
To access the glial cell speciﬁc avb3 integrin expression within the
tumor, small areas were selected and analyzed where no endothe-
lial structures were present. These areas showed once more a
signiﬁcantly higher mean staining intensity in GBMs
D C
A
100 µm 100 µm
100 µm 100 µm
*
B
*
* Figure 1. Hematoxilin & Eosin (H&E) (A) and
immunostain of integrin avb3 (C), CD31 (D) and
ﬂuorescent overlay (B) in samples of
glioblastoma. Standard H&E staining (A) shows
typical morphology of a malignant glioma.
Immunohistochemical staining of avb3 (C)i s
intense in vascular structures (asterisk) as
conﬁrmed by a consecutive section stained for
the endothelial cell marker CD31 (D). Rather,
avb3 is clearly detectable throughout the whole
section as expressed by the glial tumor cells
(arrow). A ﬂuorescent overlay picture of
another area with dense tumor growth (B)
demonstrates that the integrin avb3 (green) is
not restricted to vascular structures (red,
asterisk) but shows a ubiquitous distribution
pattern (cell nuclei blue). Scale bars: 100 mm.
Abbreviations: EP = endothelial proliferation;
M = mitosis.
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density of immunohistochemically positive tumor cells was mea-
sured in GBMs (mild: 46.31  22.23%, moderate: 2.02  2.88%,
strong: 0.23  0.49%) and LGGs (mild: 12.31  5.46%, moder-
ate: 0.01  0.01%, strong: 0%), which were signiﬁcantly different
(P < 0.05), although the smaller areas might increase the sampling
error. The latter ﬁndings indicate that the tumor cells contribute
substantially to the avb3 integrin expression.
In conclusion, GBMs demonstrated a higher expression of avb3
integrin than low-grade astrocytomas that was not only caused by a
highfocalreactivityinproliferatingmicrovesselsbutalsobystron-
ger expression in glial tumor cells. The pattern of avb3 integrin
expression depended also on the subtype of tumor. In malignant
gliomas, more than three quarters of the overall integrin expression
(about 85%) is derived from glial tumor cells.
b3 Integrin subunit expression shows an
essential difference between GBMs and LGGs in
Western blot analysis
To investigate the immunohistochemical expression of integrin
avb3expressioninmoredetail,weperformedWesternblotanalysis
fromfrozenbraintumorsamplesasdescribedinthemethods.Each
lane was loaded with an equal tissue volume of 30 nL (5 mm2 of
tissue). The Western blots were incubated with subunit speciﬁc
antibody for b3 chain and av chains.Thereby, the integrin subunits
B
CD
A
100 µm 100 µm
Figure 2. Detection of avb3 integrin in
malignant (A) and a low-grade (B) glioma and
analysis by an imaging software (C,D). The
malignant glioma (A) exhibit a much higher
expression of avb3 integrin (red) than the
low-grade glioma (B), where only very few glial
cells are immunopositive for the integrin. The
detection of the staining intensity in the
malignant glioma shows a large overall
baseline (red) expression with certain strong
(yellow) or even intense (white) expression in
microvascular structures (C). In contrast, only
some red dots can be detected in the
low-grade glioma (D). Scale bars: 100 mm
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Figure 3. Statistical analysis of the avb3
integrin immunohistochemistry in patients with
glioblastomas (GBMs) and low-grade gliomas
(LGGs) and non-CNS tumors (non-CNS). A.
Mean staining intensity of non-CNS tumors,
GBMs and LGGs. B. Fraction of mild, moderate
and strong stained tissue in GBMs and LGGs.
C. Mean staining intensity of glial tissue only in
GBMs and LGGs. D. Fraction of mild,
moderate and strong stained tissue of glial
tissue only in GBMs and LGGs. Signiﬁcant
differences (P < 0.05, Student’s t-test) are
indicated with an asterisk.
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chains were detected as weak bands at a molecular weight of about
96 kDa accompanied by their major degradation products at about
64 and 52 kDa. The heavy av chains were detectable at 137 kDa.
Further on, strong double bands were detectable at about 25 and
27 kDa, which correspond to major degradation products av light
chains.The full lengths of the av light chains are barely detectable
at about 52 kDa. Figure 4A shows the detection of integrin sub-
units from ﬁve different GBM patients (left ﬁve lanes; the one lane
on the right demonstrates CD31 and b-actin).The group of GBMs
demonstrate a heterogenous pattern of b3 chains, whereas the por-
tions of av light chains were strongly present in all samples. The
expression in low-grade astrocytomas was lower, especially the b3
chains, which were barely detectable.
The densitometric analysis (Figure 4B) of the samples, cali-
brated by the dilution series of a reference probe, revealed an
overall density of b3 chain at 96 kDa and av light chains at 25 and
27 kDa of 102.8  43.0 in GBMs (n = 20) and 69.1  30.9 in
low-grade astrocytomas (n = 5), which corroborates the immuno-
histochemical measurements (but is not statistically signiﬁcant).
By comparing the b3 subunit at 96 kDa, we found a highly signiﬁ-
cantly elevated expression in GBMs with 6.18  4.59 compared
with LGGs with 1.07  0.549 (P < 0.05; Student’s t-test, Table 1).
The expressions of av light chains at 25 and 27 kDa were not
signiﬁcantly different in GBMs (51.6  23.0 and 45.0  19.9
respectively) and in low-grade astrocytomas (43.4  35.6 and
24.6  24.6, respectively).
Further on, microvascularization was assessed by Western
blot analysis using the endothelial cell marker CD31, which
was detected at 80 kDa (Figure 4A, right lane). Densitometric
analysis demonstrated that samples of GBMs had signiﬁcantly
higher staining intensities (25.2  12.9) than LGGs (4.9  2.2,
P < 0.05). The ratio of the overall integrin avb3 detection (sum
GBMs 102.8  43.0, sum LGGs 69.1  30.9) to the amount of
CD31 demonstrated quite different values of 4.1 in GBMs and
14.1 in LGGs, which indicates that the detection of CD31 posi-
tive endothelial cells overcomes the higher expression of avb3
integrin in GBMs (Table 1). Consequently, the numerous prolifer-
ating endothelial cells do not contribute at all to the avb3 integrin
expression.
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Figure 4. Western blot analysis of subunits and degradation products of
the avb3 integrin. The Western blot analysis of ﬁve different glioblastoma
(GBM) tissue samples (A, left lanes) and densitometric analysis of inte-
grin subunits (B). In all glial tumors, degradation products of the av
subunit (av light chains) were detected as a double band at 25/27 kDa
(). Expression was constantly present but heterogeneous between
different GBMs. The b3 subunit was detected at about 96 kDa ().
Degradation products of av and b3 subunit were found at 55 kDa (). The
detection of CD31 at about 80 kDa (right ) and b-actin at about 42 kDa
(right ) is additionally demonstrated in the lane on the right. B. Densito-
metric analysis revealed signiﬁcant differences for the b3 subunit
between malignant gliomas and low-grade gliomas (LGGs) (P < 0.05;
Student’s t-test; indicated with an asterisk). The av subunit (about
137 kDa) and its degradation products (av light chains, 25/27 kDa)
showed no signiﬁcant differences between high- and low-grade gliomas.
Table 1. Densitometric analysis of integrin subunits av and b3 and microvascularization in glioblastomas (GBMs), low-grade gliomas (LGGs) and
non-CNS tumors (non-CNS). Overall density of integrin subunits av (25/27 kDa) and b3 (96 kDa) as well as the endothelial cells (CD31; 80 kDa) of the
tumors was assessed by the Western blot analysis and calibrated by a dilution series of a reference probe. In GBMs, the b3 subunit at 96 kDa showed
a signiﬁcantly elevated expression compared with LGGs (P<0.05; Student’s t-test). The amount of CD31 demonstrated quite different values in GBMs
and in LGGs, indicating microvascular proliferation.
av Light chains
b3 Subunit av +b 3 Subunit CD31 b-Actin
25 kDa 27 kDa 96 kDa 25 + 27 + 96 kDa 80 kDa 40 kDa
GBM 51.6  23.0 45.0  19.9 6.18  4.59 102.8  43.0 25.2  12.9 36.8  22.7
LGG 43.4  35.6 24.6  24.6 1.07  0.549 69.1  30.9 4.9  2.2 30.1  13.2
Non-CNS 36.2  29.0 70.0  36.1 8.1  6.2 105.3  58.0 34.6  18.4 52.5  41.0
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found in GBMs and low-grade astrocytomas
As immunohistochemical stainings and Western blot analysis
revealed an avb3 integrin expression in malignant GBMs and in a
low level in low-grade astrocytomas, we investigated the expres-
sion on mRNA level. Cryoconserved tissue of low- and high-grade
gliomas was subjected to RT-PCR as described in the materials.
Figure 5 demonstrates the PCR product after 24 to 36 recombina-
tion cycles for the subunits av and b3 in a sample of a malignant
GBM and a low-grade astrocytoma.The mRNA of subunit av was
strongly ampliﬁed in both high- and low-grade gliomas. The
mRNA of the b3 subunit was also present in both tumor entities but
ampliﬁed on a lower level. Therefore, on the mRNA level, both
malignant GBM and low-grade astrocytoma were able to express
active avb3 integrin, as suggested by the previous immunohis-
tochemistry andWestern blotting, which corroborates the previous
results of immunohistochemistry andWestern blotting.
DISCUSSION
Integrins are adhesion receptors that mediate cell–cell as well as
cell–ECM interactions associated with tumor growth and angio-
genesis in malignant gliomas (5, 23, 31, 39). However, there is still
a controversy about the extent and the distribution of avb3 integrin
expression caused by malignancy and the cell type of origin in
gliomas. In literature, 30% of glioma cells were described positive
for avb3 integrin in anaplastic astrocytomas and GBMs, whereas
LGGs did not express detectable amounts of this integrin (16–18,
38). In situ studies for the two different integrin subunits av and b3
revealed that the expression of integrin avb3 was focused more on
small blood vessels of GBMs (16, 38). One other group detected
individual glial tumor cells of GBMs to be positive for the subunits
avandb3(32).Onlyrecently,Belloet alreportedamoreprominent
expression of integrin avb3 on glioma cells but without providing a
detailedexpressionpattern(5).Yet,thisisamatterofmajorinterest
for therapeutic delivery of integrin avb3 interfering agents to
reduce tumor angiogenesis and growth (7, 9, 29, 38). The efﬁcacy
ofthisapproachisclearlydependentontheintratumoralextentand
distribution of avb3 integrin, as it has to be supposed that mainly
the endothelial cell bound avb3 integrin portion is reached by intra-
venous application.
For this reasons, the extent, distribution and pattern of integrin
avb3 expression as well as its correlation to tumor grade were
investigated. The computed immunohistochemistry and calibrated
staining analysis provided high accuracy and the possibility to
bypass the very crucial point of visual quantiﬁcation of immuno-
histochemical staining results. In GBMs, a high expression of avb3
integrin was found not only in the endothelial cells of proliferating
microvessels but also in tumor cells. The great variability of the
expression might, in part, explain why the studies that have been
carried out so far showed controversial results according to the
amount of avb3 integrin and its cellular and regional distribution
within the tumor. While previous reports focused more on the
impact of integrin avb3 on angiogenesis (5, 16), we demonstrated
that glial tumor cells themselves contribute signiﬁcantly, account-
ing for approximately 85% of the overall expression of avb3 inte-
grin. In contradiction to former studies, we were also able to detect
integrin avb3 expression even in LGGs (18), but on a signiﬁcantly
lower level and predominantly on tumor cells, as there is a lower
vascularization.
Interestingly, our miniaturized Western blot analysis revealed a
signiﬁcant difference only for the expression of the b3 subunit
between GBMs and LGGs, whereas the av subunit and its degrada-
tion products (12) showed no signiﬁcant difference between these
tumor entities.This might be caused by the fact that the integrin av
subunit is also needed with the b5 subunit to form the avb5 integrin,
which is also abundant in highly vascularized malignant gliomas
(5). Moreover, there are other b subunits (b1, b6, b8) that het-
erodimerize with the av subunit, whereas the b3 subunit in brain
tumors only partners with av and with aIIb in thrombocytes (5, 18,
23, 24, 32). Therefore, the endothelial expression of avb3 integrin
seems to be characteristic for malignant microvessel transforma-
tion, as it has already been described that the b3 subunit expression
in GBMs is most prominent in endothelial and perivascular cells
associated with tumor angiogenesis (5, 16, 18). Moreover, integrin
av
b3
LGG GBM
M 24 3 15 M 12 345 bp
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Figure 5. PCR analysis of avb3 integrin
subunits. PCR analysis of avb3 integrin subunits
av (A,B) and b3 (C,D) of a glioblastoma (GBM;
A,C) and low-grade glioma (LGG; B,D) after
different recombination cycles. Lane 1: 24
cycles, lane 2: 27 cycles, lane 3: 30 cycles, lane
4: 33 cycles and lane 5: 36 recombination
cycles. Standard PCR revealed that both
subunits av (690 bp) and b3 (510 bp) are
synthesized in high as well as low-grade
gliomas indicating that both tumor entities are
able to express a functionally active avb3
integrin receptor. Marker (M) was a 50 bp ladder
(Novagen, Perfect DNA ladder).
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where it was found to correlate with the dedifferentiation and inva-
sive behavior of invasive endothelial cells as well as tumor cells (5,
8, 9, 11, 37). As MMP-2 is an important metalloproteinase for the
invasion and dissemination of tumor cells, its functional relation-
ship to the avb3 integrin expression might play a key role in tumor
progression (30). However, recent studies on genetically altered
mouse models raise the question whether the integrin avb3 is truly
proangiogenic and necessary for tumor angiogenesis, as mice
lacking either one of these subunits are viable and fertile and show
extensive vascularization (1, 22, 35).
Despite these still unanswered questions, antiangiogenic therapy
with integrin avb3 antagonists has reached clinical phase I/IIa trials
for the patients with malignant gliomas. Therefore, minute detec-
tion and quantiﬁcation of avb3 integrin expression could be a pre-
requisite for the selection of patients suitable for this kind of addi-
tional therapy to analyze the potential relationship between avb3
expression and antitumor activity. In the context of a modern per-
sonalized cancer therapy, the beneﬁts should be calculated for each
individual patient, especially, as GBMs show a very heterogenous
expression of avb3 integrin, which ranges from only mild to very
strong. This might also include the noninvasive detection of avb3
expression in gliomas through molecular imaging methods (2–4,
19, 20, 30). Thus, future studies will have to conﬁrm that either
tumor angiogenesis or higher malignancy in gliomas in fact corre-
late with the amount of integrin avb3 expression. This could also
lead to new diagnostic and therapeutic approaches for integrin-
interfering agents.
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